CoChat

The Challenges of Acute Interstitial Nephritis: Time to Standardize

Open access

The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.

Abstract

Acute interstitial nephritis (AIN) is a well-known cause of acute kidney disease (AKD) and CKD and is associated with progression to ESKD (1⇓⇓⇓⇓–6). Accordingly, it represents an important problem for clinicians caring for these patients. AIN is primarily an immune-mediated kidney injury triggered by use of certain medications, in particular antibiotics, PPIs, NSAIDs, and immune checkpoint inhibitors (ICPIs), or by autoimmune diseases, such as Sjogren syndrome, sarcoidosis, IgG4-related tubulointerstitial disease, and TINU. In developed countries, medications are the most common cause of AIN (>70%), whereas the number approximates 50% in developing countries. Infectious agents are a less common cause of AIN, except in developing countries. The overall incidence of AIN in kidney biopsy registries is 2%–5%, whereas AIN is observed in approximately 15%–20% of patients with AKI or AKD who undergo kidney biopsy (1⇓–3). The actual number is likely higher as many patients with AKI/AKD do not undergo biopsy and are presumed to have acute tubular injury (ATI). Importantly, diagnosing AIN clinically is often quite challenging, making kidney biopsy a frequent requirement to definitively confirm the diagnosis and guide therapy (Figure 1). Furthermore, delayed or missed AIN diagnosis leads to ongoing inflammation with resulting interstitial fibrosis, tubular atrophy, and permanent kidney damage, which may be the explanation for CKD occurring in 40%–60% of patients after an episode of AIN (4,5). Approximately 2% of CKD is considered to be due to AIN, which is equivalent to 10 million prevalent worldwide cases. Furthermore, AIN is the primary cause of ESKD in 3%–4% of incident patients (6). It is one of the few potentially treatable causes of AKI if identified and treated early. In view of these data, three key challenges that limit the diagnosis and management of patients suspected of having …

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.34067/kid.0001742021

Cites

27 of 27 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 27 references

Cited by

See all 27

Metadata

Authors
Moledina, D. G., & Perazella, M. A.
Affiliations
  • Yale University (US)
  • Veterans Health Administration (US)
Venue
Kidney360
Published
2021-06
Volume
2
Issue
6
Pages
1051-1055
ISSN
2641-7650 (ISSN-L)
OpenAlex
W3150376309
Cited by
25
References
27
Citations by year
2026: 5 · 2025: 8 · 2024: 7 · 2023: 1 · 2022: 3 · 2021: 1
FWCI
2.06
Type
journal article
Language
en
Open access
Locations
  • Kidney360 (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Nephrology › Acute Kidney Injury Research
  • Health Sciences › Medicine › Nephrology › Nephrotoxicity and Medicinal Plants
  • Health Sciences › Medicine › Nephrology › Renal Diseases and Glomerulopathies
Keywords
acute interstitial nephritis, acute kidney injury, drug-induced nephrotoxicity, immune checkpoint inhibitors, renal biopsy, diagnosis, end-stage renal disease, chronic kidney disease, interstitial fibrosis, standardization of care
MeSH terms
Humans, Nephritis, Interstitial

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The Challenges of Acute Interstitial Nephritis: Time to Standardize. https://app.cochat.ai/papers/10.34067/kid.0001742021
The paper
Moledina, D. G., & Perazella, M. A. (2021). The Challenges of Acute Interstitial Nephritis: Time to Standardize. Kidney360. https://doi.org/10.34067/kid.0001742021

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.